Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of 20 mg rivaroxaban tablets in healthy Thai volunteers under fed conditions
TCTR20190503001Phase 1Completed
- Sponsor
- Novartis
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban (2 arms), sponsored by Novartis. Primary endpoints: Cmax, AUC0-t and 2 more. Started Aug 2019; status: completed.
02
Drugs
rivaroxaban
Beyond the preview
Go deeper on TCTR20190503001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190503001.